Key facts
- This page summarizes Barry D. Quart's Form 4 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Jan 2023, 16:10.
Barry D. Quart - 18 Jan 2023 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- HRTX
- Reported as of
- 18 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Jan 2023, 16:10:01 UTC
- Prior SEC filing
- 17 Jan 2023
- Next SEC filing
- 08 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Peraza Attorney-in-fact for Barry D. Quart
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barry D. Quart filed Form 4 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 20 Jan 2023.
Change
- Previous filing in this sequence was filed on 17 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +850,000
- Change %
- Price
- $0.000000
- Shares after
- 850,000
- Date
- 18 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 850,000
- Exercise price
- $3.13
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.